

BBI Board Message January 2023, Cambridge

Recent global events have made the pharmaceutical industry, the biotechnology sector and the wider life sciences ecosystem to be at the forefront of breaking news in our society. A key focus has been in vaccine development and roll out, as well as in new drug development. The BBI has been at the vanguard of scientific management education for almost a decade now and will continue to develop the next generation of global leaders, who will be able to deliver a positive impact in our society. This last year has been an opportunity to reflect on past achievements, present challenges and future priorities to maintain the prominence of our Business School at the centre of a European cluster of excellence.

Prospective BBI candidates will engage with a broad and international learning community committed to educate and prepare our students for their professional growth through our career impact programme. That is why, in 2020, we have achieved a record of 98% of our MBA students finding internship positions and/or new job opportunities. Our mission will be continue growing young professionals in developing lifelong benefits in their professional careers. The range of visiting lecturers, our regular network events and the overall team-building work that our students experience provide full immersion into the course during the MBA academic year.

This experience, strengthens the job future opportunities for our students within global Life Science's companies, enhancing our students' capabilities and talent to an international level of competence. The primary focus of our courses is to enable our students to acquire a practical experience of making business decisions but also to be ethically aware and contribute to the overall social sustainability of our planet. We believe that these new skills and accomplishments are much appreciated by our commercial partners and recruiters more widely.

As part of our global expansion within Europe, the opportunity of having three Campuses focused on life sciences will enhance the range of options and experiences for our students. In Barcelona, the Campus will continue to focus on new drug discovery and development opportunities will ensure the continuing specialisation of our students, who will become highly qualified to accept the present challenges in the pharmaceutical industry.



We have become a European centre of reference in specialised knowledge in the healthcare segment recognised by the many companies worldwide, which is a current trend that we will maintain. These continuous improvements would not be possible without a global career engagement team, our MBA specialists and the support our faculty. The Cambridge Campus will have a broader remit across the Life Science's ecosystem.

Our Mexico Campus contributes to the global objective of the Business School connecting the pharmaceutical and biotechnology industry in Latin America with the major innovation hubs in Europe and the United States. Is the educational centre of reference in healthcare contributing to the development of national talent, the growth of internal innovation and promoting global transactions.

We look forward to welcoming our students, who will remain close to our community, partners, alumni and companies. We thank you as always for your constant support and trust.

Juan R. Garcia



Board Chairman

Biotechnology Business Institute

